A fixed-dose combination (FDC) of an antispasmodic (Camylofin) and a non-steroidal anti-inflammatory drug (NSAID) of the fenamate class (Mefenamic Acid). It is primarily indicated for the relief of moderate to severe pain associated with smooth muscle spasms, particularly in dysmenorrhea, renal colic, and biliary colic. The combination provides synergistic action by relieving both the spasm and the associated inflammatory pain.
Adult: One tablet (Camylofin 50mg + Mefenamic Acid 250mg) every 6-8 hours, as required for pain. Should be taken with or after food. The maximum duration of continuous use should not exceed 7 days without medical supervision.
Note: Take with a full glass of water, preferably with food or milk to minimize gastrointestinal irritation. Do not crush or chew. The tablet should be swallowed whole.
Camylofin is a smooth muscle relaxant with dual action: 1) Anticholinergic (antimuscarinic) action blocks acetylcholine at muscarinic receptors in smooth muscle, reducing spasms. 2) Direct musculotropic action via calcium channel blockade, leading to relaxation independent of autonomic innervation. Mefenamic Acid is a NSAID that provides analgesic, anti-inflammatory, and antipyretic effects by non-selectively inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins, which are key mediators of pain, inflammation, and fever.
Pregnancy: Category C (first and second trimester): Use only if potential benefit justifies potential risk to the fetus. Animal studies show adverse effects. Category D (third trimester): CONTRAINDICATED. NSAIDs may cause premature closure of the ductus arteriosus, oligohydramnios, and inhibit labor.
Driving: May cause dizziness, drowsiness, or blurred vision. Patients should not drive or operate machinery until they know how the medication affects them.
| Warfarin/Acenoocumarol | Increased risk of bleeding due to displacement from protein binding and antiplatelet effect of Mefenamic Acid. | Major |
| Lithium | Mefenamic Acid can decrease renal clearance of lithium, leading to toxicity. | Major |
| Methotrexate | Mefenamic Acid can reduce renal excretion of methotrexate, increasing its toxicity. | Major |
| Other NSAIDs (e.g., Aspirin, Ibuprofen) | Increased risk of GI toxicity and reduced antiplatelet effect of aspirin. | Major |
| ACE Inhibitors (e.g., Ramipril) / ARBs (e.g., Telmisartan) | Mefenamic Acid may reduce their antihypertensive effect and increase risk of renal impairment. | Moderate |
| Diuretics (e.g., Furosemide) | Risk of nephrotoxicity and reduced diuretic efficacy. | Moderate |
| Corticosteroids (e.g., Prednisolone) | Greatly increased risk of GI ulceration and bleeding. | Major |
| Anticholinergics (e.g., Atropine, Tricyclic Antidepressants) | Additive anticholinergic side effects (dry mouth, urinary retention, constipation) with Camylofin. | Moderate |
| SSRIs (e.g., Sertraline) | Increased risk of upper GI bleeding. | Moderate |
Same composition (Camylofin (50mg) + Mefenamic Acid (250mg)), different brands: